Pediatrix Medical Group (NYSE:MD) Rating Increased to Buy at StockNews.com

StockNews.com upgraded shares of Pediatrix Medical Group (NYSE:MD) from a hold rating to a buy rating in a research note issued to investors on Wednesday.

Several other analysts have also recently commented on MD. Truist Financial raised their target price on Pediatrix Medical Group from $13.00 to $16.00 and gave the stock a “hold” rating in a research report on Monday, November 4th. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a research report on Monday, November 4th. UBS Group increased their price objective on Pediatrix Medical Group from $10.50 to $16.50 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Mizuho lifted their target price on shares of Pediatrix Medical Group from $13.00 to $15.00 and gave the stock a “neutral” rating in a report on Monday, November 4th. Finally, Jefferies Financial Group lifted their price target on Pediatrix Medical Group from $14.00 to $18.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, Pediatrix Medical Group has an average rating of “Hold” and a consensus price target of $16.10.

Pediatrix Medical Group Stock Performance

Shares of MD stock opened at $14.15 on Wednesday. The company has a quick ratio of 1.42, a current ratio of 1.42 and a debt-to-equity ratio of 0.83. The stock has a 50-day simple moving average of $12.53 and a 200 day simple moving average of $9.85. Pediatrix Medical Group has a fifty-two week low of $6.62 and a fifty-two week high of $16.41.

Pediatrix Medical Group (NYSE:MD) last released its quarterly earnings data on Friday, November 1st. The company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.07. The business had revenue of $511.20 million during the quarter, compared to analyst estimates of $498.87 million. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The company’s revenue was up .9% compared to the same quarter last year. During the same period last year, the company posted $0.29 EPS. On average, equities analysts predict that Pediatrix Medical Group will post 1.25 earnings per share for the current year.

Insider Transactions at Pediatrix Medical Group

In related news, EVP Mary Ann E. Moore sold 8,108 shares of the stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $16.00, for a total transaction of $129,728.00. Following the completion of the sale, the executive vice president now owns 135,810 shares in the company, valued at $2,172,960. This trade represents a 5.63 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Mark S. Ordan sold 27,600 shares of Pediatrix Medical Group stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total transaction of $423,660.00. Following the completion of the transaction, the director now owns 138,683 shares of the company’s stock, valued at $2,128,784.05. This trade represents a 16.60 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 53,808 shares of company stock valued at $751,277. Company insiders own 2.00% of the company’s stock.

Hedge Funds Weigh In On Pediatrix Medical Group

Several hedge funds have recently added to or reduced their stakes in MD. Rubric Capital Management LP boosted its stake in shares of Pediatrix Medical Group by 797.0% in the 2nd quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company’s stock valued at $61,532,000 after purchasing an additional 7,241,400 shares during the last quarter. Dana Investment Advisors Inc. grew its holdings in Pediatrix Medical Group by 80.3% during the 2nd quarter. Dana Investment Advisors Inc. now owns 1,023,136 shares of the company’s stock worth $7,725,000 after acquiring an additional 455,785 shares during the period. Boston Partners raised its position in shares of Pediatrix Medical Group by 34.0% during the 1st quarter. Boston Partners now owns 1,786,434 shares of the company’s stock valued at $17,702,000 after acquiring an additional 453,254 shares during the last quarter. Weiss Asset Management LP lifted its stake in shares of Pediatrix Medical Group by 50.5% in the 3rd quarter. Weiss Asset Management LP now owns 912,818 shares of the company’s stock valued at $10,580,000 after purchasing an additional 306,143 shares during the period. Finally, Cubist Systematic Strategies LLC boosted its position in shares of Pediatrix Medical Group by 639.4% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 290,336 shares of the company’s stock worth $2,192,000 after purchasing an additional 251,072 shares during the last quarter. Institutional investors own 97.71% of the company’s stock.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.